FDA Approves Adcetris for Most Common Subtypes of Cutaneous T-cell Lymphoma
News
The U.S. Food and Drug Administration (FDA) has approved Seattle Genetics’ Adcetris (brentuximab vedotin) for the treatment of adults with the two most common subtypes of cutaneous T-cell lymphoma (CTCL) — ... Read more